CA
RIGL icon

Clearstead Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Clearstead Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314 Buy
+8
New +$247 ﹤0.01% 3061
2026
Q1 		– Sell
-306
Closed -$13.1K – 2735
2025
Q4 		$13.1K Buy
+306
New +$11.5K ﹤0.01% 1824
2025
Q3 		– Sell
-58
Closed -$1.09K – 3218
2025
Q2 		$1.09K Buy
+58
New +$1.1K ﹤0.01% 2423

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's RIGL Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 8 shares worth $314. The stake represents ﹤0.01% of the portfolio and ranks #3061 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in RIGL as recently as Q4 2025.

Clearstead Advisors first reported a position in RIGL in Q2 2025 and has held it in 3 quarters since. The position peaked at $13.1K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Clearstead Advisors held 8 shares of Rigel Pharmaceuticals worth $314 as of Q2 2026.
  • Rigel Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3061 holding.
  • Clearstead Advisors first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Rigel Pharmaceuticals position peaked at $13.1K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.